Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 6, 2009, Pages 541-564

  De Winter, Brenda C M ^a   Van Gelder, Teun ^a   Sombogaard, Ferdi ^a   Shaw, Leslie M ^b   Van Hest, Reinier M ^a   Mathot, Ron A A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Mechanism based pharmacokinetic model; Mycophenolic acid; Population pharmacokinetics; Protein binding; Renal transplant recipients

Indexed keywords

CYCLOSPORIN; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PLASMA PROTEIN; SERUM ALBUMIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISSOCIATION CONSTANT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG PROTEIN BINDING; ENTEROHEPATIC CIRCULATION; FEMALE; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION;

ADULT; AGED; AREA UNDER CURVE; BIOTRANSFORMATION; COMPUTER SIMULATION; CREATININE; CYCLOSPORINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENTEROHEPATIC CIRCULATION; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN; TACROLIMUS; YOUNG ADULT;

EID: 72349088234     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9136-6     Document Type: Article

References (42)

1. G Knoll 2008 Trends in kidney transplantation over the past decade Drugs 68 Suppl 1 3 10 10.2165/00003495-200868001-00002 18442296 (Pubitemid 351601432)
2. AC Allison EM Eugui 1996 Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF) Clin Transplant 10 1 Pt 2 77 84 1:STN:280:DyaK283lt1SltQ%3D%3D 8680053
3. BC de Winter RA Mathot RM van Hest T van Gelder 2007 Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? Expert Opin Drug Metab Toxicol 3 2 251 261 10.1517/17425255.3.2.251 17428154 (Pubitemid 47316040)
4. T van Gelder YL Meur LM Shaw M Oellerich D DeNofrio C Holt DW Holt B Kaplan D Kuypers B Meiser B Toenshoff RD Mamelok 2006 Therapeutic drug monitoring of mycophenolate mofetil in transplantation Ther Drug Monit 28 2 145 154 10.1097/01.ftd.0000199358.80013.bd 16628123 (Pubitemid 44314941)
5. T van Gelder HT Silva JW de Fijter K Budde D Kuypers G Tyden A Lohmus C Sommerer A Hartmann Y Le Meur M Oellerich DW Holt B Tonshoff P Keown S Campbell RD Mamelok 2008 Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial Transplantation 86 8 1043 1051 10.1097/TP.0b013e318186f98a 18946341
6. Y Le Meur M Buchler A Thierry S Caillard F Villemain S Lavaud I Etienne PF Westeel BH de Ligny L Rostaing E Thervet JC Szelag JP Rerolle A Rousseau G Touchard P Marquet 2007 Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation Am J Transplant 7 11 2496 2503 10.1111/j.1600-6143.2007.01983.x 1:CAS:528:DC%2BD2sXhtlakt73N 17908276 (Pubitemid 47566324)
7. LM Shaw DW Holt M Oellerich B Meiser T van Gelder 2001 Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion Ther Drug Monit 23 4 305 315 10.1097/00007691-200108000-00001 1:CAS:528:DC%2BD3MXmtFGnsrk%3D 11477311 (Pubitemid 32708913)
8. VC Cox MH Ensom 2003 Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 25 2 137 157 10.1097/00007691-200304000-00003 1:CAS:528:DC%2BD3sXitlKit7k%3D 12657908 (Pubitemid 36373421)
9. RE Bullingham AJ Nicholls BR Kamm 1998 Clinical pharmacokinetics of mycophenolate mofetil Clin Pharmacokinet 34 6 429 455 10.2165/00003088- 199834060-00002 1:CAS:528:DyaK1cXkt1eisro%3D 9646007 (Pubitemid 28273453)
10. RM van Hest T van Gelder AG Vulto RA Mathot 2005 Population pharmacokinetics of mycophenolic acid in renal transplant recipients Clin Pharmacokinet 44 10 1083 1096 10.2165/00003088-200544100-00006 16176120 (Pubitemid 41356393)
11. B Kaplan HU Meier-Kriesche G Friedman S Mulgaonkar S Gruber M Korecka KL Brayman LM Shaw 1999 The effect of renal insufficiency on mycophenolic acid protein binding J Clin Pharmacol 39 7 715 720 10.1177/00912709922008353 1:CAS:528:DC%2BD3cXivFaitA%3D%3D 10392326
12. DR Kuypers Y Vanrenterghem JP Squifflet M Mourad D Abramowicz M Oellerich V Armstrong M Shipkova J Daems 2003 Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil Ther Drug Monit 25 5 609 622 10.1097/00007691- 200310000-00011 1:CAS:528:DC%2BD3sXnsFanurg%3D 14508385 (Pubitemid 37238896)
13. LT Weber T Lamersdorf M Shipkova PD Niedmann M Wiesel LB Zimmerhackl A Staskewitz E Schutz O Mehls M Oellerich VW Armstrong B Tonshoff 1999 Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients Ther Drug Monit 21 5 498 506 10.1097/00007691-199910000-00002 1:CAS:528:DyaK1MXmvV2qtbg%3D 10519445 (Pubitemid 29468315)
14. FM Gonzalez-Roncero MA Gentil M Brunet G Algarra P Pereira V Cabello M Peralvo 2005 Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency Transplant Proc 37 9 3749 3751 10.1016/j.transproceed.2005.09.202 1:CAS:528:DC%2BD28XksVSm 16386526 (Pubitemid 43015154)
15. LM Shaw R Mick I Nowak M Korecka KL Brayman 1998 Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function J Clin Pharmacol 38 3 268 275 1:CAS:528:DyaK1cXisFWgtrs%3D 9549665
16. Z Jiao JY Zhong M Zhang XJ Shi YQ Yu WY Lu 2007 Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies Eur J Clin Pharmacol 63 1 27 37 10.1007/s00228-006-0215-y 1:CAS:528:DC%2BD28XhtlCksb3K 17093994 (Pubitemid 46025470)
17. AG Johnson RJ Rigby PJ Taylor CE Jones J Allen K Franzen MC Falk D Nicol 1999 The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients Clin Pharmacol Ther 66 5 492 500 10.1016/S0009-9236(99)70012-3 1:CAS:528:DyaK1MXotVCjt7o%3D 10579476
18. T van Gelder J Klupp MJ Barten U Christians RE Morris 2001 Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid Ther Drug Monit 23 2 119 128 10.1097/00007691-200104000-00005 11294511 (Pubitemid 32240138)
19. G Filler M Zimmering I Mai 2000 Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression Pediatr Nephrol 14 2 100 104 10.1007/s004670050021 1:STN:280:DC%2BD3c7kvVequw%3D%3D 10684356
20. DA Hesselink RM van Hest RA Mathot F Bonthuis W Weimar RW de Bruin T van Gelder 2005 Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2 Am J Transplant 5 5 987 994 10.1046/j.1600-6143.2005.00779.x 1:CAS:528:DC%2BD2MXksValtLg%3D 15816878 (Pubitemid 40571246)
21. BA Kiberd J Lawen AD Fraser T Keough-Ryan P Belitsky 2004 Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation Am J Transplant 4 7 1079 1083 10.1111/j.1600-6143.2004.00455.x 1:CAS:528:DC%2BD2cXmtFGksLY%3D 15196064 (Pubitemid 38868597)
22. MD Hale AJ Nicholls RE Bullingham R Hene A Hoitsma JP Squifflet W Weimar Y Vanrenterghem FJ Van de Woude GA Verpooten 1998 The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation Clin Pharmacol Ther 64 6 672 683 10.1016/S0009-9236(98)90058-3 1:CAS:528:DyaK1MXjslWgsQ%3D%3D 9871432 (Pubitemid 29011387)
23. LT Weber M Shipkova VW Armstrong N Wagner E Schutz O Mehls LB Zimmerhackl M Oellerich B Tonshoff 2002 The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy J Am Soc Nephrol 13 3 759 768 11856782
24. BA Atcheson PJ Taylor DW Mudge DW Johnson CM Hawley SB Campbell NM Isbel PI Pillans SE Tett 2005 Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant Br J Clin Pharmacol 59 3 271 280 10.1111/j.1365-2125.2004.02235.x 1:CAS:528:DC%2BD2MXjtVOgu7o%3D 15752372 (Pubitemid 40388081)
25. T van Gelder LB Hilbrands Y Vanrenterghem W Weimar JW de Fijter JP Squifflet RJ Hene GA Verpooten MT Navarro MD Hale AJ Nicholls 1999 A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 2 261 266 10.1097/00007890- 199907270-00018 10440399 (Pubitemid 29360288)
26. I Tsina F Chu K Hama M Kaloostian YL Tam T Tarnowski B Wong 1996 Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma J Chromatogr B Biomed Appl 675 1 119 129 10.1016/0378-4347(95)00343-6 1:CAS:528:DyaK28XnslSjug%3D%3D 8634753 (Pubitemid 26036976)
27. I Nowak LM Shaw 1995 Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics Clin Chem 41 7 1011 1017 1:CAS:528:DyaK2MXms1Gltbo%3D 7600680
28. F Sombogaard RHN Van Schaik RA Mathot K Budde M Van der Werf AG Vulto W Weimar P Glander L Essioux T Van Gelder 2009 Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphisms Pharmacogenet Genomics 19 8 626 634 10.1097/FPC.0b013e32832f5f1b 1:CAS:528:DC%2BD1MXptFCktLw%3D 19617864
29. P Glander F Sombogaard K Budde T van Gelder P Hambach L Liefeldt C Lorkowski M Mai HH Neumayer AG Vulto RA Mathot 2009 Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells Ther Drug Monit 31 3 351 359 10.1097/FTD.0b013e31819c3f3d 1:CAS:528:DC%2BD1MXmt1ejtL0%3D 19333146
30. EN Jonsson MO Karlsson 1999 Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 1 51 64 10.1016/S0169-2607(98)00067-4 1:STN:280: DyaK1M3htVShsw%3D%3D 10195646 (Pubitemid 29049052)
31. BC de Winter I Neumann RM van Hest T van Gelder RA Mathot 2009 Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease Ther Drug Monit 31 3 382 390 10.1097/FTD.0b013e3181a23f1a 19363460
32. D Cockroft M Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 10.1159/000180580
33. PR Jadhav JV Gobburu 2005 A new equivalence based metric for predictive check to qualify mixed-effects models Aaps J 7 3 E523 E531 10.1208/aapsj070353 16353930 (Pubitemid 41631736)
34. BA Atcheson PJ Taylor CM Kirkpatrick SB Duffull DW Mudge PI Pillans DW Johnson SE Tett 2004 Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia Ther Drug Monit 26 3 284 286 10.1097/00007691-200406000-00011 1:CAS:528:DC%2BD2cXksVKgtr8%3D 15167629 (Pubitemid 38703015)
35. LM Shaw M Korecka S Aradhye R Grossman L Bayer C Innes A Cucciara C Barker A Naji A Nicholls K Brayman 2000 Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable J Clin Pharmacol 40 6 624 633 10.1177/00912700022009260 1:CAS:528:DC%2BD3cXktFCqtrc%3D 10868313
36. RM van Hest T van Gelder AG Vulto LM Shaw RA Mathot 2009 Pharmacokinetic modeling of the plasma protein binding of mycophenolic acid in renal transplant recipients Clin Pharmacokinet 48 7 463 476 10.2165/11312600-000000000-00000 19691368
37. M Danhof G Alvan SG Dahl J Kuhlmann G Paintaud 2005 Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers Pharm Res 22 9 1432 1437 10.1007/s11095-005-5882-3 1:CAS:528: DC%2BD2MXptVWltbc%3D 16132354 (Pubitemid 41215882)
38. JP Tillement F Lhoste JF Giudicelli 1978 Diseases and drug protein binding Clin Pharmacokinet 3 2 144 154 10.2165/00003088-197803020-00004 1:STN:280:DyaE1c7kslWmtg%3D%3D 25156
39. LZ Benet BA Hoener 2002 Changes in plasma protein binding have little clinical relevance Clin Pharmacol Ther 71 3 115 121 10.1067/mcp.2002.121829 1:CAS:528:DC%2BD38XjtFChtbc%3D 11907485 (Pubitemid 34271114)
40. K Bowalgaha JO Miners 2001 The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes Br J Clin Pharmacol 52 5 605 609 10.1046/j.0306-5251.2001.01487.x 1:CAS:528:DC%2BD3MXoslaqs74%3D 11736871
41. RM van Hest RA Mathot MD Pescovitz R Gordon RD Mamelok T van Gelder 2006 Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients J Am Soc Nephrol 17 3 871 880 10.1681/ASN.2005101070 16452491
42. M Naesens H de Loor Y Vanrenterghem DR Kuypers 2007 The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide Transplantation 84 3 362 373 10.1097/01.tp.0000276936.14041.6c 1:CAS:528:DC%2BD2sXovFOrur0%3D 17700162 (Pubitemid 47258325)